|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LAS1L |
Gene summary for LAS1L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LAS1L | Gene ID | 81887 |
| Gene name | LAS1 like ribosome biogenesis factor | |
| Gene Alias | Las1 | |
| Cytomap | Xq12 | |
| Gene Type | protein-coding | GO ID | GO:0000460 | UniProtAcc | Q9Y4W2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 81887 | LAS1L | LZE4T | Human | Esophagus | ESCC | 2.17e-09 | 3.98e-01 | 0.0811 |
| 81887 | LAS1L | LZE5T | Human | Esophagus | ESCC | 2.64e-03 | 2.38e-01 | 0.0514 |
| 81887 | LAS1L | LZE7T | Human | Esophagus | ESCC | 4.57e-12 | 7.20e-01 | 0.0667 |
| 81887 | LAS1L | LZE8T | Human | Esophagus | ESCC | 4.13e-04 | 1.58e-01 | 0.067 |
| 81887 | LAS1L | LZE20T | Human | Esophagus | ESCC | 6.38e-03 | 2.80e-01 | 0.0662 |
| 81887 | LAS1L | LZE22T | Human | Esophagus | ESCC | 5.66e-03 | 3.20e-01 | 0.068 |
| 81887 | LAS1L | LZE24T | Human | Esophagus | ESCC | 1.19e-18 | 4.92e-01 | 0.0596 |
| 81887 | LAS1L | LZE21T | Human | Esophagus | ESCC | 4.64e-03 | 2.80e-01 | 0.0655 |
| 81887 | LAS1L | LZE6T | Human | Esophagus | ESCC | 4.21e-03 | 2.39e-01 | 0.0845 |
| 81887 | LAS1L | P1T-E | Human | Esophagus | ESCC | 1.29e-03 | 2.88e-01 | 0.0875 |
| 81887 | LAS1L | P2T-E | Human | Esophagus | ESCC | 3.09e-17 | 4.29e-01 | 0.1177 |
| 81887 | LAS1L | P4T-E | Human | Esophagus | ESCC | 8.33e-12 | 3.67e-01 | 0.1323 |
| 81887 | LAS1L | P5T-E | Human | Esophagus | ESCC | 2.20e-13 | 4.01e-01 | 0.1327 |
| 81887 | LAS1L | P8T-E | Human | Esophagus | ESCC | 3.00e-14 | 3.06e-01 | 0.0889 |
| 81887 | LAS1L | P9T-E | Human | Esophagus | ESCC | 3.33e-07 | 3.71e-01 | 0.1131 |
| 81887 | LAS1L | P10T-E | Human | Esophagus | ESCC | 1.53e-10 | 3.04e-01 | 0.116 |
| 81887 | LAS1L | P11T-E | Human | Esophagus | ESCC | 3.51e-06 | 4.36e-01 | 0.1426 |
| 81887 | LAS1L | P12T-E | Human | Esophagus | ESCC | 5.21e-18 | 4.59e-01 | 0.1122 |
| 81887 | LAS1L | P15T-E | Human | Esophagus | ESCC | 3.03e-10 | 2.73e-01 | 0.1149 |
| 81887 | LAS1L | P16T-E | Human | Esophagus | ESCC | 3.80e-19 | 4.26e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
| GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
| GO:001607212 | Liver | HCC | rRNA metabolic process | 193/7958 | 236/18723 | 1.26e-35 | 1.14e-32 | 193 |
| GO:000636421 | Liver | HCC | rRNA processing | 185/7958 | 225/18723 | 8.14e-35 | 6.45e-32 | 185 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:004227322 | Liver | HCC | ribosomal large subunit biogenesis | 64/7958 | 72/18723 | 2.31e-16 | 2.03e-14 | 64 |
| GO:000047011 | Liver | HCC | maturation of LSU-rRNA | 26/7958 | 28/18723 | 2.82e-08 | 6.43e-07 | 26 |
| GO:0090305 | Liver | HCC | nucleic acid phosphodiester bond hydrolysis | 152/7958 | 261/18723 | 1.90e-07 | 3.46e-06 | 152 |
| GO:00004601 | Liver | HCC | maturation of 5.8S rRNA | 29/7958 | 35/18723 | 1.12e-06 | 1.66e-05 | 29 |
| GO:002261320 | Oral cavity | OSCC | ribonucleoprotein complex biogenesis | 333/7305 | 463/18723 | 8.28e-48 | 5.24e-44 | 333 |
| GO:004225420 | Oral cavity | OSCC | ribosome biogenesis | 230/7305 | 299/18723 | 3.22e-41 | 6.80e-38 | 230 |
| GO:000636410 | Oral cavity | OSCC | rRNA processing | 172/7305 | 225/18723 | 1.57e-30 | 1.24e-27 | 172 |
| GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
| GO:001607210 | Oral cavity | OSCC | rRNA metabolic process | 176/7305 | 236/18723 | 6.51e-29 | 3.24e-26 | 176 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| GO:004227320 | Oral cavity | OSCC | ribosomal large subunit biogenesis | 61/7305 | 72/18723 | 1.52e-15 | 1.06e-13 | 61 |
| GO:00004706 | Oral cavity | OSCC | maturation of LSU-rRNA | 26/7305 | 28/18723 | 3.39e-09 | 7.66e-08 | 26 |
| GO:00903052 | Oral cavity | OSCC | nucleic acid phosphodiester bond hydrolysis | 142/7305 | 261/18723 | 2.90e-07 | 4.43e-06 | 142 |
| GO:00004602 | Oral cavity | OSCC | maturation of 5.8S rRNA | 28/7305 | 35/18723 | 8.71e-07 | 1.19e-05 | 28 |
| GO:0022613110 | Oral cavity | LP | ribonucleoprotein complex biogenesis | 259/4623 | 463/18723 | 7.20e-48 | 2.25e-44 | 259 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| LAS1L | PERI | Cervix | ADJ | KRT18,NRN1,HIST1H4C, etc. | 2.36e-01 |  |
| LAS1L | MYOFIB | Cervix | CC | KRT18,NRN1,HIST1H4C, etc. | 3.18e-01 |  |
| LAS1L | MYOFIB | Cervix | HSIL_HPV | KRT18,NRN1,HIST1H4C, etc. | 1.12e-01 |  |
| LAS1L | PVA | Pancreas | ADJ | CRYBG3,CARD11,CSNK2A2, etc. | 2.21e-02 |  |
| LAS1L | MSC | Pancreas | ADJ | CRYBG3,CARD11,CSNK2A2, etc. | 0.00e+00 | |
| LAS1L | INCAF | Pancreas | ADJ | CRYBG3,CARD11,CSNK2A2, etc. | 0.00e+00 | |
| LAS1L | CAF | Pancreas | ADJ | CRYBG3,CARD11,CSNK2A2, etc. | 0.00e+00 | |
| LAS1L | FIB | Pancreas | ADJ | CRYBG3,CARD11,CSNK2A2, etc. | 0.00e+00 | |
| LAS1L | PVA | Pancreas | PanIN | CRYBG3,CARD11,CSNK2A2, etc. | 6.16e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LAS1L | SNV | Missense_Mutation | c.1945N>C | p.Thr649Pro | p.T649P | Q9Y4W2 | protein_coding | tolerated(0.24) | benign(0.146) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
| LAS1L | SNV | Missense_Mutation | rs769442653 | c.743N>T | p.Gly248Val | p.G248V | Q9Y4W2 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-A8-A08C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| LAS1L | SNV | Missense_Mutation | novel | c.1370N>T | p.Ser457Phe | p.S457F | Q9Y4W2 | protein_coding | deleterious(0.02) | benign(0.365) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| LAS1L | SNV | Missense_Mutation | novel | c.2015N>T | p.Thr672Ile | p.T672I | Q9Y4W2 | protein_coding | tolerated(0.37) | benign(0.005) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LAS1L | SNV | Missense_Mutation | c.1814N>C | p.Arg605Thr | p.R605T | Q9Y4W2 | protein_coding | tolerated(0.19) | benign(0.012) | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | |
| LAS1L | SNV | Missense_Mutation | novel | c.206N>T | p.Ala69Val | p.A69V | Q9Y4W2 | protein_coding | deleterious(0) | possibly_damaging(0.819) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| LAS1L | SNV | Missense_Mutation | c.2065N>T | p.Thr689Ser | p.T689S | Q9Y4W2 | protein_coding | tolerated(0.69) | benign(0) | TCGA-BH-A0AZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
| LAS1L | SNV | Missense_Mutation | c.608G>A | p.Arg203Lys | p.R203K | Q9Y4W2 | protein_coding | tolerated(0.62) | benign(0) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| LAS1L | SNV | Missense_Mutation | novel | c.206N>T | p.Ala69Val | p.A69V | Q9Y4W2 | protein_coding | deleterious(0) | possibly_damaging(0.819) | TCGA-E9-A22B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| LAS1L | SNV | Missense_Mutation | rs201107712 | c.1933N>A | p.Val645Met | p.V645M | Q9Y4W2 | protein_coding | deleterious(0.01) | probably_damaging(0.944) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |